Biotechnology company Moderna (NASDAQ: MRNA) will be reporting results this Friday before market hours. Here’s what to look for.
Moderna beat analysts’ revenue expectations by 32.2% last quarter, reporting revenues of $1.02 billion, down 45.1% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance missing analysts’ expectations significantly.
Is Moderna a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Moderna’s revenue to decline 31.7% year on year to $660.2 million, improving from the 65.6% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$2.64 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Moderna has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 30.9% on average.
Looking at Moderna’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Biogen’s revenues decreased 7.1% year on year, beating analysts’ expectations by 3.6%, and Amgen reported revenues up 8.6%, topping estimates by 4.1%. Biogen traded up 4.6% following the results while Amgen was also up 8.2%.
Read our full analysis of Biogen’s results here and Amgen’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.6% on average over the last month. Moderna is up 1.5% during the same time and is heading into earnings with an average analyst price target of $38.40 (compared to the current share price of $40.18).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
